29709-35-1

Usage

Uses

Used in Pharmaceutical Synthesis:
2-(1H-PYRROL-1-YL)-1-ETHANAMINE is used as a synthetic intermediate for the preparation of dihydropyrrolo[2′,1′:3,4]pyrazino[2,1-a]isoindolones. These complex molecules are synthesized by reacting 2-(1H-PYRROL-1-YL)-1-ETHANAMINE with 2-formylbenzoic acids or 2-acetylbenzoic acid through N-acyliminium cation aromatic cyclizations. The resulting products, such as those previously listed as CBR00085, have potential applications in the development of new drugs and therapeutic agents.
Used in Chemical Research:
In addition to its pharmaceutical applications, 2-(1H-PYRROL-1-YL)-1-ETHANAMINE is also utilized in chemical research as a starting material for the synthesis of various heterocyclic compounds. Its unique structure allows for further functionalization and modification, making it a valuable tool in the development of novel chemical entities with potential applications in various industries, including materials science, agrochemistry, and specialty chemicals.

InChI:InChI=1/C6H10N2/c7-3-6-8-4-1-2-5-8/h1-2,4-5H,3,6-7H2

Upstream product

• 86241-05-6 2-(1H-pyrrol-1-yl)acetonitrile 
• 89532-47-8 pyrrol-1-yl-acetic acid amide 
• 69309-33-7 1,4-bis-(dimethylamino)-1,3-butadiene 
• 107-15-3 ethylenediamine 
• 73627-16-4 N-[2-(1H-pyrrol-1-yl)ethyl]acetamide 
• 109-97-7 pyrrole 
• 689-98-5 chloroethylamine 
• 7440-44-0 pyrographite 
• 696-59-3 cis,trans-2,5-dimethoxytetrahydrofuran 
• 98019-88-6 3,4-Dibrom-butyraldehyd 
• 870-24-6 2-chloroethanamine hydrochloride 

Downstream Products

• 71257-37-9 3,4-dihydropyrrolo[1,2-a]-pyrazine 
• 73627-27-7 1-(3,4,5-Trimethoxyphenyl)-1,2,3,4-tetrahydropyrrolo<1,2-a>pyrazine 
• 127418-82-0 1-<2-(4'-nitrobenzoyl)aminoethyl>pyrrole 
• 136927-87-2 1-(2-(N-benzoylamino)ethyl)pyrrole 
• 945655-30-1 6-chloro-N-(2-pyrrol-1-yl-ethyl)nicotinamide 
• 473257-38-4 4,5-difluoro-3-(3,5-dimethylphenylsulfonyl)-indole-2-(2-(1-pyrrolo)-ethyl)-carboxamide 
• 1117686-29-9 4-{[4-(2,6-dimethylpyridin-3-yl)oxypyridin-2-yl]amino}-N-(2-pyrrol-1-ylethyl)benzamide 
• 1174068-78-0 3,4-Dihydro-1H-pyrrolo[1,2-a]pyrazine-2-carboxylic acid tert-butyl ester 
• 1190130-48-3 1-(4-nitrobenzyl)-1-trifluoromethyl-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine 
• 1190130-49-4 1-(4-chlorobenzyl)-1-trifluoromethyl-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine 
• 1226978-12-6 8-phenyl-5,6-dihydro-13bH-pyrrolo[2',1':3,4]pyrazino[2,1-a]isoquinoline 

Relevant academic research and scientific papers

Synthesis of Size-Tunable Hollow Polypyrrole Nanostructures and Their Assembly into Folate-Targeting and pH-Responsive Anticancer Drug-Delivery Agents

Chemotherapeutic drugs currently used in clinical settings have high toxicity, low specificity, and short half-lives. Herein, polypyrrole-based anticancer drug nanocapsules were prepared by tailoring the size of the nanoparticles with a template method, controlling drug release by means of an aromatic imine, increasing nanoparticle stability through PEGylation, and improving tumor-cell selectivity by folate mediation. The nanoparticles were characterized by TEM and dynamic light scattering. α-Folate receptor expression levelsof tumor cells and normal cells were investigated by western blot and quantitative polymerase chain reaction analyses. Flow cytometry and fluorescence imaging were used to verify the cell uptake of the different-sized nanoparticles. From the different-sized polypyrrole nanoparticles, the optimally functionalized nanoparticles of 180 nm hydrodynamic diameter were chosen and further usedfor in vitroandin vivotests. The nanoparticles showed excellent biocompatibility and the drug-loaded nanoparticles exhibited effective inhibition of tumor cell growth in vitro. Moreover, the drug-loaded nanoparticles showed substantially enhanced accumulation in tumor regions and effectively inhibitedin vivotumor growth. Furthermore, the nanoparticles showed reduced doxorubicin-induced toxicity andno significant side effects in normal organs of tumor-bearing mice, as measured by body-weight shifts and evaluationof drug distribution. Overall, the functionalized nanoparticles are promising nanocarriers for tumor-targeting drug delivery.

Construction of pyrrole- and indole-fused CF3-piperazine derivatives

A series of pyrrole- and indole-fused trifluoromethyl-functionalized piperazine derivatives were constructed in moderate to good yields with excellent chemoselectivities via a Pictet-Spengler reaction under mild and operationally simple conditions. The synthetic utility of this protocol was further extended by the facile preparation of indole-fused CF3-1,4-diazocane and enantioenriched CF3-piperazines via a vinylogous Pictet-Spengler reaction and an asymmetric Pictet-Spengler reaction, respectively.

EIS INHIBITORS

Compounds and compositions are disclosed, which are useful as inhibitors of acetyltransferase Eis, a mediator of kanamycin resistance in Mycobacterium tuberculosis.

Compound as potassium channel modulator

The invention relates to a compound as a potassium channel modulator, which is a compound of a formula (I) or a pharmaceutically acceptable salt thereof. The compound or the pharmaceutically acceptable salt thereof is effective for curing and preventing diseases and symptoms influenced by the activity of potassium ion channels.

Design, synthesis and evaluation of novel N-phenylbutanamide derivatives as KCNQ openers for the treatment of epilepsy

KCNQ (Kv7) has emerged as a validated target for the development of novel anti-epileptic drugs. In this paper, a series of novel N-phenylbutanamide derivatives were designed, synthesized and evaluated as KCNQ openers for the treatment of epilepsy. These compounds were evaluated for their KCNQ opening activity in vitro and in vivo. Several compounds were found to be potent KCNQ openers. Compound 1 with favorable in vitro activity was submitted to evaluation in vivo. Results showed that compound 1 owned significant anti-convulsant activity with no adverse effects. It was also found to posses favorable pharmacokinetic profiles in rat. This research may provide novel potent compounds for the discovery of KCNQ openers in treating epilepsy.

Combating Enhanced Intracellular Survival (Eis)-Mediated Kanamycin Resistance of Mycobacterium tuberculosis by Novel Pyrrolo[1,5-a]pyrazine-Based Eis Inhibitors

Tuberculosis (TB) remains one of the leading causes of mortality worldwide. Hence, the identification of highly effective antitubercular drugs with novel modes of action is crucial. In this paper, we report the discovery and development of pyrrolo[1,5-a]p

Organocatalytic enantioselective multicomponent synthesis of pyrrolopiperazines

The first organocatalytic multicomponent synthesis of enantioenriched pyrrolopiperazines is reported. These biologically relevant fused tricyclic products were obtained under catalytic iminium activation through a reaction sequence involving an enantioselective Michael addition followed by an iminium ion trapping via Pictet-Spengler cyclization (MAPS sequence). Substantial possibilities for variation on the three reaction partners [β-keto ester, enal and N-(2-aminoethyl)pyrrole] along with excellent enantioselectivities are the highlights of the present transformation.

PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF

A phthalazinone ketone derivative as represented by formula (I), a preparation method thereof, a pharmaceutical composition containing the derivative, a use thereof as a poly (ADP-ribose) polymerase (PARP) inhibitor, and a cancer treatment method thereof.

PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF

A phthalazinone ketone derivative as represented by formula (I), a preparation method thereof, a pharmaceutical composition containing the derivative, a use thereof as a poly (ADP-ribose) polymerase (PARP) inhibitor, and a cancer treatment method thereof are described.

Substituted Tetrahydropyrrolopyrazine Compounds

Tetrahydropyrrolopyrazine compounds, methods for their preparation, pharmaceutical compositions containing such compounds, and a method of using such compounds for the treatment of pain and other conditions mediated at least partially by Bradykinin 1 rece